April 26, 2017 4:32 AM ET

Pharmaceuticals

Company Overview of Corium International, Inc.

Company Overview

Corium International, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening. The company’s products under pipeline comprise Twirla, a combination hormonal contraceptive patch, that has completed Phase III clinical trial to deliver ethinyl estradiol and levonorgestrel hormones; MicroCor hPTH(1-34), a transdermal system that has completed Phase 1 an...

235 Constitution Drive

Menlo Park, CA 94025

United States

Founded in 1995

212 Employees

Phone:

650-298-8255

Fax:

650-298-8012

Key Executives for Corium International, Inc.

Chief Executive Officer, President and Director
Age: 64
Total Annual Compensation: $462.5K
Chief Financial Officer
Age: 54
Total Annual Compensation: $366.5K
Chief Business Officer
Age: 49
Total Annual Compensation: $335.1K
Chief Technology Officer and Vice President of Research & Development
Age: 52
Total Annual Compensation: $312.7K
Compensation as of Fiscal Year 2016.

Corium International, Inc. Key Developments

Corium International, Inc. Presents at 16th Annual Needham Healthcare Conference, Apr-05-2017 10:00 AM

Corium International, Inc. Presents at 16th Annual Needham Healthcare Conference, Apr-05-2017 10:00 AM. Venue: Westin Grand Central Hotel, New York, New York, United States. Speakers: Peter D. Staple, Chief Executive Officer, President and Director.

Corium International, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended December 31, 2016; Provides Product Revenue Outlook for the Fiscal Year 2017

Corium International, Inc. reported unaudited consolidated earnings results for the first quarter ended December 31, 2016. For the quarter, total revenues were $6,969,000 against $7,537,000 a year ago. Loss from operations was $8,413,000 against $7,450,000 a year ago. Loss before income taxes was $10,427,000 against $9,397,000 a year ago. Net loss and comprehensive loss was $10,429,000 against $9,400,000 a year ago. Net loss per share attributable to common stockholders, basic and diluted was $0.46 against $0.42 a year ago. The decrease in total revenues resulted primarily from a decrease in contract research and development revenues, as well as a decrease in product revenues. Of the total revenue, product revenues for the quarter were $5.7 million, compared with $6 million for the same period in 2016. The decrease in product Revenue was primarily due to a $1.4 million decrease in Fentanyl product sale as the transition of inventory and forecasting to Endo as well as continued market competition resulted in an accumulation of inventory by Endo, all of which resulted in a corresponding reduction in product shipment. The company provided product revenue outlook for 2017. The company currently expects total product revenues for 2017 to be roughly 10% lower than those for 2016.

Corium International, Inc., Q1 2017 Earnings Call, Feb 13, 2017

Corium International, Inc., Q1 2017 Earnings Call, Feb 13, 2017

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Corium International, Inc., please visit www.coriumgroup.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.